PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials

Gynecologic Oncology

Volumn 142, Issue 3, 2016, Pages 588-596

  Crafton, S M ^a   Bixel, K ^a   Hays, J L ^a,b  

^a Division of Gynecologic Oncology   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; ENDOMETRIUM CANCER; ENZYME INHIBITION; FEMALE; HUMAN; MONOTHERAPY; OVARY CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; ENZYMOLOGY; GENITAL NEOPLASMS, FEMALE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84979263828     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.05.003     Document Type: Review

References (62)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J. Clin. 65:1 (2015), 5–29.
2. [2] Howlader, N., N.A., Krapcho, M., Garshell, J., Miller, D., Altekruse, S.F., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D.R., Chen, H.S., Feuer, E.J., Cronin, K.A., (eds.) SEER Cancer Statistics Review, 1975-2012, National Cancer Institute, Bethesda, MD.
3. [3] Sawyers, C., Targeted cancer therapy. Nature 432:7015 (2004), 294–297.
4. [4] Krishnakumar, R., Kraus, W.L., The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol. Cell 39:1 (2010), 8–24.
5. [5] Rouleau, M., et al. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10:4 (2010), 293–301.
6. [6] Schreiber, V., et al. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7:7 (2006), 517–528.
7. [7] Konstantinopoulos, P.A., et al. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 5:11 (2015), 1137–1154.
8. [8] Scott, C.L., Swisher, E.M., Kaufmann, S.H., Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J. Clin. Oncol. 33:12 (2015), 1397–1406.
9. [9] Murai, J., et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72:21 (2012), 5588–5599.
10. [10] Ljungman, M., Targeting the DNA damage response in cancer. Chem. Rev. 109:7 (2009), 2929–2950.
11. [11] Lord, C.J., Tutt, A.N., Ashworth, A., Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu. Rev. Med. 66 (2015), 455–470.
12. [12] Ledermann, J., et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15:8 (2014), 852–861.
13. [13] Lynparza: FDA prescribing information. Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl.pdf.
14. [14] Morton, L.M., et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood 121:15 (2013), 2996–3004.
15. [15] Audeh, M.W., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:9737 (2010), 245–251.
16. [16] Kaufman, B., et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33:3 (2015), 244–250.
17. [17] Kaye, S.B., et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol. 30:4 (2012), 372–379.
18. [18] Pujade-Lauraine, E., Ann. Oncol. 27:supp 1 (2016), i63–i65.
19. [19] Cancer Genome Atlas Research, N., Integrated genomic analyses of ovarian carcinoma. Nature 474:7353 (2011), 609–615.
20. [20] Bast, R.C. Jr., Hennessy, B., Mills, G.B., The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer 9:6 (2009), 415–428.
21. [21] Chen, S., Parmigiani, G., Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 25:11 (2007), 1329–1333.
22. [22] Liu, J.F., Konstantinopoulos, P.A., Matulonis, U.A., PARP inhibitors in ovarian cancer: current status and future promise. Gynecol. Oncol. 133:2 (2014), 362–369.
23. [23] FDA briefing document: oncologic drugs advisory committee meeting., June 25, 2014 Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM402207.pdf.
24. [24] Rucaparib Gets, F.D.A., Breakthrough therapy status for ovarian cancer. Oncol. Times 37:9 (2015), 4–5.
25. [25] European Medicines Agency: European publica assessment report (EPAR) for Lynparza., October 24 2014 Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003726/human_med_001831.jsp&mid=WC0b01ac058001d124.
26. [26] Fong, P.C., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361:2 (2009), 123–134.
27. [27] Fong, P.C., et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28:15 (2010), 2512–2519.
28. [28] Ledermann, J., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366:15 (2012), 1382–1392.
29. [29] Matulonis, U.A., et al. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multi-study analysis of response rates and safety. Ann. Oncol., 2016.
30. [30] Coleman, R.L., et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - an NRG oncology/gynecologic oncology group study. Gynecol. Oncol. 137:3 (2015), 386–391.
31. [31] Shapira-Frommer, R., et al. A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation. ASCO American Society of Clinical Oncology Annual Meeting, 2015 (cited Abstract 5513; Available from: http://meetinglibrary.asco.org/content/150826-156).
32. [32] McNeish, I.A., et al. Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. ASCO American Society of Clinical Oncology Annual Meeting, 2015 (cited Abstract 5508; Available from: http://meetinglibrary.asco.org/content/150121-156).
33. [33] Mills, G.B., Timms, K.M., Reid, J.E., Gutin, A.S., Krivak, T.C., Hennessy, B., Paul, J., Brown, R.J.S., Lanchbury, J.S., Stronach, E.A., Homologous recombination deficiency score shows superior association with outcome compared with its individual score components in platinum-treated serous ovarian cancer. Society of Gynecologic Oncology Annual Meeting, 2016 (Abstract #2).
34. [34] Rottenberg, S., et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. U. S. A. 105:44 (2008), 17079–17084.
35. [35] Del Conte, G., et al. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br. J. Cancer 111:4 (2014), 651–659.
36. [36] Lee, J.M., et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J. Natl. Cancer Inst., 106(6), 2014, dju089.
37. [37] Samol, J., et al. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Investig. New Drugs 30:4 (2012), 1493–1500.
38. [38] Khan, O.A., et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br. J. Cancer 104:5 (2011), 750–755.
39. [39] Rajan, A., et al. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin. Cancer Res. 18:8 (2012), 2344–2351.
40. [40] Dent, R.A., et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res., 15(5), 2013, R88.
41. [41] Oza, A.M., et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 16:1 (2015), 87–97.
42. [42] van der Noll, R., et al. Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. Br. J. Cancer 113:3 (2015), 396–402.
43. [43] Ivy, S.P., et al. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. Expert Opin. Investig. Drugs 25:5 (2016), 597–611.
44. [44] Liu, J.F., et al. A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur. J. Cancer 49:14 (2013), 2972–2978.
45. [45] Liu, J.F., et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 15:11 (2014), 1207–1214.
46. [46] Kummar, S., et al. Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clin. Cancer Res. 21:7 (2015), 1574–1582.
47. [47] Landrum, L.M., et al. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: an NRG oncology/gynecologic oncology group study. Gynecol. Oncol. 140:2 (2016), 204–209.
48. [48] Ang, J.E., et al. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin. Cancer Res. 19:19 (2013), 5485–5493.
49. [49] Fleming, G.F., Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J. Clin. Oncol. 25:20 (2007), 2983–2990.
50. [50] Okuda, T., et al. Genetics of endometrial cancers. Obstet. Gynecol. Int., 2010, 2010, 984013.
51. [51] Cancer Genome Atlas Research, N., et al. Integrated genomic characterization of endometrial carcinoma. Nature 497:7447 (2013), 67–73.
52. [52] Mutter, G.L., et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl. Cancer Inst. 92:11 (2000), 924–930.
53. [53] Dedes, K.J., et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci. Transl. Med., 2(53), 2010, 53ra75.
54. [54] Shen, W.H., et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128:1 (2007), 157–170.
55. [55] Forster, M.D., et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat. Rev. Clin. Oncol. 8:5 (2011), 302–306.
56. [56] Villalona-Calero, M.A., et al. Veliparib alone or in combination with mitomycin C in patients with solid tumors with functional deficiency in homologous recombination repair. J. Natl. Cancer Inst., 108(7), 2016.
57. [57] Torre, L.A., B.F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics. CA Cancer J. Clin. 65:2 (2012), 87–108.
58. [58] Michels, J., et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res. 73:7 (2013), 2271–2280.
59. [59] Smith, H.J., et al. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. Gynecol. Oncol. 139:1 (2015), 59–62.
60. [60] Secord, A.A., et al. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. Int. J. Gynecol. Cancer 23:5 (2013), 846–852.
61. [61] SGO clinical practice statement: genetic testing for ovarian cancer., October 2014 Available from https://www.sgo.org/clinical-practice/guidelines/genetic-testing-for-ovarian-cancer/.
62. [62] Genetics/familial high-risk assessment: breast and ovarian. NCCN Clinical Practice Guidelines in Oncology, February 2016.